Phase 2 study of treatment for spinal cord injury(ASIA impairment scale A,B) with autologous mononuclear cells derived from bone marrow

Phase 2 study of treatment for spinal cord injury(ASIA impairment scale A,B) with autologous mononuclear cells derived from bone marrow - Phase 2 study of treatment for spinal cord injury with autologous mononuclear cells

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015741

Enrollment

Registered

2014-11-23

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal cord injury

Interventions

Intrathecal single injection of autologous mononuclear cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with spinal cord injuries classified as A or B on the ASIA impairment scale 2.Patients within 3 weeks after injury 3.Patients with partial spinal cord injury demonstrated by diagnostic imaging 4.Patients aged between 20 and 60 years at the acquisition of informed consent 5.Patients who submitted written informed consent by themselves

Exclusion criteria

Exclusion criteria: 1.Patients with a completely transected spinal cord 2.Patient with spinal shock 3.Patients with central spinal cord injury 4.Patients with organ failure with a SOFA score of 3 points or higher 5.Patients in whom hepatitis B, hepatitis C, human immunodeficiency virus infection, adult T-cell leukemia, or parvovirus B19 infection could not be ruled out 6.Patients with malignant tumor or a history of malignant tumor within 5 years 7.Patients with one of the following diseases/disorders: ?Myeloproliferative disorder or myelodysplastic syndrome ?Autoimmune disease ?Spinal stenosis ?Limb paralysis due to central nervous system disorder not attributed to spinal cord injury ?Poorly controlled psychiatric disorder 8.Patients who were participating in other clinical trials or who completed participation within 6 months 9.Patients who were pregnant or possibly pregnant 10.Other patients who were judged to be ineligible by the investigators

Design outcomes

Primary

Measure	Time frame
To investigate the recovery of motor and sensory function after transplantaion of bone marrow-derived mononuclear cells into cerebrospinal fluid of patients with subacute spinal injury	—

Secondary

Measure	Time frame
Type and grade of adverse events Frequency of adverse events	—

Countries

Japan

Contacts

Public ContactYoshihisa Suzuki

The Tazuke Kofukai Medical Research Institute, Kitano Hospital Plastic surgery, 5 th laboratory

yo-suzuki@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026